Clinical characteristics and risk factors of acute lymphoblastic leukemia in children with severe infection during maintenance treatment

Cancer Med. 2023 Oct;12(19):19372-19382. doi: 10.1002/cam4.6495. Epub 2023 Sep 28.

Abstract

Background: Infection is the most common adverse event of acute lymphoblastic leukemia (ALL) treatment and is also one of the main causes of death.

Methods: To investigate the clinical characteristics and risk factors of severe infections during the maintenance phase of ALL treatment, we conducted a retrospective study.

Results: A total of 181 children were eligible and 46 patients (25.4%) suffered from 51 events of severe infection, most of which occurred in the first half year of the maintenance phase (52.9%). The most common infection was pulmonary infection (86.3%) followed by bloodstream infection (19.6%). The main symptoms of ALL patients with pulmonary infection were fever, cough, and shortness of breath. The main manifestations of computer tomography (CT) were ground glass shadow (56.8%), consolidation shadow (27.3%), and streak shadow (25%). Multivariate binary logistic regression analysis showed that agranulocytosis, agranulocytosis ≥7 days, anemia, and low globulin level were independent risk factors for severe infection during the maintenance phase (all p < 0.05).

Conclusions: Taken together, blood routine examinations and protein levels should be monitored regularly for ALL patients in the maintenance phase, especially in the first 6 months. For ALL patients with risk factors, preventive anti-infective or supportive therapies can be given as appropriate to reduce the occurrence of severe infections.

Keywords: acute lymphoblastic leukemia; children; maintenance phase; risk factors; severe infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Agranulocytosis* / drug therapy
  • Agranulocytosis* / etiology
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Child
  • Humans
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / complications
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Retrospective Studies
  • Risk Factors